Home
Resources
Diseases
COVID-19
Hepatitis B
Human papillomavirus (HPV)
Malaria
Measles
Mpox
Pneumococcal disease
RSV (Respiratory syncytial virus)
Compendium
Hexavalent vaccines
HPV vaccines
Malaria vaccines
PCV vaccines
RSV vaccines
Training
Vaccine Portfolio Optimization and Prioritization (VPOP)
Evaluation
The Tool
The Tutorial
The Dashboard
SYSVAC
About
Registry
E-learning courses
News
Webinars
Network
Steering Committee
Vision and Mission
Map
Meetings
Partners
Join us
Home
Resources
Resources
Selected
COVID-19
Type of publications
Guidelines (1)
NITAG documentation (359)
Reports (1)
SAGE documentation (34)
Scientific publications (4)
Systematic reviews (SYSVAC) (1190)
Regions
Africa (62)
Americas (192)
Eastern Mediterranean (12)
Europe (160)
Global (1)
South-East Asia (11)
Western Pacific (39)
Diseases
COVID-19 (1589)
Chikungunya (13)
Cholera (35)
Cytomegalovirus (1)
Dengue (43)
Diphtheria (90)
Ebola (19)
Escherichia coli (ETEC) (2)
Haemophilus influenzae type B (71)
Hepatitis A (69)
Hepatitis B (171)
Hepatitis C (5)
Hepatitis E (5)
Herpes simplex (1)
Herpes zoster (77)
HIV / AIDS (10)
Human papillomavirus (HPV) (537)
Influenza (629)
Japanese encephalitis (34)
Lyme disease, Borreliosis (2)
Malaria (33)
Measles (144)
Meningococcal disease (155)
Moraxella catarrhalis (1)
Mpox (58)
Mumps (50)
Pertussis (120)
Pneumococcal disease (305)
Poliomyelitis (94)
Q fever (1)
Rabies (33)
Rotavirus (121)
RSV (Respiratory syncytial virus) (69)
Rubella (69)
Salmonella (3)
Shigella (1)
Smallpox (16)
Streptococcus group B (6)
Tetanus (71)
Tick-borne encephalitis (14)
Tuberculosis (83)
Typhoid (32)
Varicella (77)
Yellow fever (44)
Zika (1)
Show more
Methodological quality (AMSTAR 2)
High (13)
Moderate (9)
Low (130)
Critically low (729)
Not applicable (309)
1589 results found
2022
∙
SAGE
Meeting of the Strategic Advisory Group of Experts on Immunization, April 2022: conclusions and recommendations
2022
∙
SAGE
Interim statement on the use of additional booster doses of Emergency Use Listed mRNA vaccines against COVID-19
2022
∙
NACI
Updated recommendations on the use of COVID-19 vaccine booster doses in children 5 to 11 years of age and concurrent vaccine administration
2022
∙
Haute Autorité de Santé
Vaccination strategy against Covid-19: Place of the VLA2001 vaccine
2022
∙
Haute Autorité de Santé
Vaccination strategy against Covid-19: Place of the VidPrevtyn Beta vaccine
2022
∙
Haute Autorité de Santé
Booster vaccine strategy against Covid-19
2022
∙
Haute Autorité de Santé
Vaccination strategy against Covid-19: Place of the Nuvaxovid vaccine in the booster strategy
2022
∙
Haute Autorité de Santé
Vaccination strategy against Covid-19: role of the bivalent Spikevax Original / Omicron BA.4/BA.5 vaccine (mRNA-1273.222)
2022
∙
Christoph Steffen, Louise Henaff, Shalini Desai, Noni MacDonald, Anna-Lea Kahn, Christopher Morgan, Folake Olayinka, Ruth Faden
COVID-19 Vaccine Policy Development in a Sample of 44 Countries- Key Findings from a December 2021 Survey of National Immunization Technical Advisory Groups (NITAGs)
2022
∙
ATAGI
ATAGI recommendations on use of the Pfizer bivalent (Original/Omicron BA.1) COVID-19 vaccine
Home
Resources
Diseases
Compendium
Training
Evaluation
SYSVAC
News
Webinars
Network
Sign in / Register
